Yang Kui, Zhao Yang, Du Yonghao, Tang Ruixiang
Department of General Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710000, China.
Department of Oncology, Southwest Hospital, Third Military Medical University, Chongqing 400000, China.
J Oncol. 2021 Jan 13;2021:8842554. doi: 10.1155/2021/8842554. eCollection 2021.
Although the Hippo pathway and CD133 have been reported to play pertinent roles in a variety of cancer, knowledge about their contribution to radiation resistance in small-cell lung cancer (SCLC) is limited. In this first-of-a-kind study, we have reported the expression of key Hippo pathway proteins in SCLC patients by immunohistochemical staining. We assessed the involvement of yes-associated protein 1 (YAP1) in radiation resistance by Cell Counting Kit-8 (CCK-8) and flow cytometry. In addition, we analysed the impact of CD133 on radiotherapy for SCLC. The mammalian Ste20-like serine/threonine kinase 2(MST2), pMST2, and pYAP1 in the Hippo pathway were not significantly associated with the disease stage and survival time in patients with SCLC. However, the pYAP1 expression showed some significance in the "YAP/TAZ subgroup" of SCLC patients. The proportion of CD133 in the SCLC cells was controlled by the YAP1 expression. The CD133 and YAP1 levels were significantly correlation with each other in tissues of SCLC patients. We sorted and isolated the CD133 and CD133cells in H69 and found that the cell surface glycoprotein may be associated with the radiation resistance of SCLC.In summary, we have firstly reported the expression of key Hippo pathway proteins in SCLC patients. Furthermore, we also identified that CD133 may be controlled by the expression of YAP1 in the Hippo pathway and that CD133 may be associated with the radiation resistance of SCLC.
尽管据报道河马通路和CD133在多种癌症中发挥相关作用，但关于它们对小细胞肺癌（SCLC）放射抗性的贡献的知识有限。在这项首创的研究中，我们通过免疫组织化学染色报告了SCLC患者中关键河马通路蛋白的表达。我们通过细胞计数试剂盒-8（CCK-8）和流式细胞术评估了Yes相关蛋白1（YAP1）在放射抗性中的作用。此外，我们分析了CD133对SCLC放疗的影响。河马通路中的哺乳动物Ste20样丝氨酸/苏氨酸激酶2（MST2）、pMST2和pYAP1与SCLC患者的疾病分期和生存时间无显著相关性。然而，pYAP1表达在SCLC患者的“YAP/TAZ亚组”中显示出一定意义。SCLC细胞中CD133的比例受YAP1表达的控制。SCLC患者组织中CD133和YAP1水平彼此显著相关。我们在H69中分选并分离了CD133和CD133细胞，发现细胞表面糖蛋白可能与SCLC的放射抗性有关。总之，我们首次报告了SCLC患者中关键河马通路蛋白的表达。此外，我们还确定CD133可能受河马通路中YAP1表达的控制，且CD133可能与SCLC的放射抗性有关。
